- Home
- CVM vs RNAZ Comparison
CVM vs RNAZ Comparison
Compare CVM & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVM | RNAZ |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 27.9M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVM | RNAZ |
|---|---|---|
| Price | $2.16 | $1.68 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 197.3K | 46.1K |
| Earning Date | 11-05-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $264,033.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.45 | N/A |
| 52 Week Low | $0.89 | $1.52 |
| 52 Week High | $10.39 | $15.94 |
Technical Indicators
Market Signals| Indicator | CVM | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 37.11 |
| Support Level | $1.01 | $1.58 |
| Resistance Level | $4.84 | $2.39 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | 0.08 | 0.10 |
| Stochastic Oscillator | 48.51 | 18.39 |
Price Performance
Historical ComparisonAbout CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.